Общий доступ

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

CJ Lord, ANJ Tutt, A Ashworth

Annual review of medicine 66 (1), 455-470, 2015

Финансирование: Cancer Research UK, Wellcome Trust, Susan G. Komen

Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways

V Vichapat, C Gillett, IS Fentiman, A Tutt, L Holmberg, M Lüchtenborg

European Journal of Cancer 47 (13), 1919-1927, 2011

Финансирование: Cancer Research UK, Chief Scientist Office, Scottish Executive

Reply to J. Veeck et al

TA Yap, JS De Bono, SB Kaye, A Tutt, A Ashworth, JHM Schellens

Journal of Clinical Oncology 28 (29), e565-e566, 2010

Финансирование: Cancer Research UK

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC …

S Irshad, C Gillett, SE Pinder, RP A’hern, M Dowsett, IO Ellis, JMS Bartlett, ...

Breast cancer research and treatment 144, 331-341, 2014

Финансирование: Cancer Research UK, National Institute for Health Research, UK

The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point

L Kalinowski, G Viale, S Domchek, A Tutt, PC Lucas, SR Lakhani

Pathology 54 (5), 511-516, 2022

Финансирование: National Health and Medical Research Council, Australia

134 статьи доступны в некоторых источниках

Signatures of mutational processes in human cancer

LB Alexandrov, S Nik-Zainal, DC Wedge, SAJR Aparicio, S Behjati, ...

nature 500 (7463), 415-421, 2013

Финансирование: US National Institutes of Health, Wellcome Trust

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...

Annals of oncology 24 (9), 2206-2223, 2013

Финансирование: US National Institutes of Health

[HTML] nejm.org

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ...

New England Journal of Medicine 361 (2), 123-134, 2009

Финансирование: Cancer Research UK

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...

Annals of oncology 26 (8), 1533-1546, 2015

Финансирование: US National Institutes of Health, Susan G. Komen

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ...

Nature 534 (7605), 47-54, 2016

Финансирование: US Department of Energy, US National Institutes of Health, National Fund for …

[HTML] cell.com

Mutational processes molding the genomes of 21 breast cancers

S Nik-Zainal, LB Alexandrov, DC Wedge, P Van Loo, CD Greenman, ...

Cell 149 (5), 979-993, 2012

Финансирование: US National Institutes of Health

The landscape of cancer genes and mutational processes in breast cancer

PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ...

Nature 486 (7403), 400-404, 2012

Финансирование: US National Institutes of Health, Research Foundation (Flanders), National …

[PDF] nature.com

Pan-cancer analysis of whole genomes

Nature 578 (7793), 82-93, 2020

Финансирование: US National Institutes of Health, Cancer Research UK, UK Medical Research …

[PDF] cell.com

The life history of 21 breast cancers

S Nik-Zainal, P Van Loo, DC Wedge, LB Alexandrov, CD Greenman, ...

Cell 149 (5), 994-1007, 2012

Финансирование: US National Institutes of Health, Research Foundation (Flanders)

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...

Annals of Oncology 28 (8), 1700-1712, 2017

Финансирование: US National Institutes of Health, Cancer Research UK

[HTML] nejm.org

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ...

New England Journal of Medicine 384 (25), 2394-2405, 2021

Финансирование: US National Institutes of Health, Cancer Research UK, National Institute for …

[PDF] researchgate.net

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ...

Journal of clinical oncology 28 (15), 2512-2519, 2010

Финансирование: Cancer Research UK

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

H Davies, D Glodzik, S Morganella, LR Yates, J Staaf, X Zou, ...

Nature medicine 23 (4), 517-525, 2017

Финансирование: US National Institutes of Health, Netherlands Organisation for Scientific …

[PDF] thelancet.com

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...

The Lancet Oncology 19 (1), 27-39, 2018

Финансирование: British Heart Foundation, Cancer Research UK, UK Medical Research Council …